Treatment of cancer-associated thrombosis.
Review published in Blood (2013)
Abstract
Therapeutic options for the management of venous thromboembolism (VTE) in patients with cancer remain very limited. Although low-molecular-weight heparin monotherapy has been identified as a simple and efficacious regimen compared with an initial parenteral anticoagulant followed by long-term therapy with a vitamin K antagonist, many clinical questions remain unanswered. These include optimal duration of anticoagulant therapy, treatment of recurrent VTE, and the treatment of patients with concurrent bleeding or those with a high risk of bleeding. Treatment recommendations from consensus clinical guidelines are largely based on retrospective reports or extrapolated data from the noncancer population with VTE, as randomized controlled trials focused on cancer-associated thrombosis are sorely lacking. Furthermore, with improvements in imaging technology and extended survival duration of patients with cancer, we are encountering more unique challenges, such as the management of incidental VTE. Clinicians should be aware of the limitations of the novel oral anticoagulants and avoid the use of these agents because of the paucity of evidence in the treatment of cancer-associated thrombosis.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Therapeutic options for the management of venous thromboembolism (VTE) in patients with cancer remain very limited. Although low-molecular-weight heparin monotherapy has been identified as a simple and efficacious regimen compared with an initial parenteral anticoagulant followed by long-term...
Por qué esto importa para la hirudoterapia
Este artículo de revisión aborda el manejo del tromboembolismo venoso asociado al cáncer, señalando que la monoterapia con heparina de bajo peso molecular sigue siendo la piedra angular en comparación con la anticoagulación parenteral seguida de antagonistas de la vitamina K, mientras que muchas cuestiones clínicas —duración óptima, tratamiento del TEV recurrente, manejo de pacientes con riesgo hemorrágico— permanecen sin respuesta debido a la escasez de ensayos controlados aleatorizados en poblaciones oncológicas. Los autores desaconsejan el uso de nuevos anticoagulantes orales en este contexto dada la evidencia insuficiente. Para el ámbito de ASH, este artículo trata la farmacoterapia antitrombótica de forma general, pero no contiene ninguna referencia a sanguijuelas, hirudoterapia o al secretoma de la sanguijuela; cualquier relevancia se limita al panorama general del manejo anticoagulante sin una conexión específica con los terapéuticos derivados de la sanguijuela.
Citación
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026